<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>EASD - Le Fonti New Pharma Italy</title>
	<atom:link href="https://www.newpharmaitaly.it/tag/easd/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.newpharmaitaly.it/tag/easd/</link>
	<description>Il portale delle news in ambito farmaceutico</description>
	<lastBuildDate>Wed, 14 Nov 2018 15:57:48 +0000</lastBuildDate>
	<language>it-IT</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.newpharmaitaly.it/wp-content/uploads/2022/12/cropped-favicon-new-pharma-italy-32x32.jpg</url>
	<title>EASD - Le Fonti New Pharma Italy</title>
	<link>https://www.newpharmaitaly.it/tag/easd/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Boehringer Ingelheim e Lilly presentano i risultati dello studio CARMELINA®</title>
		<link>https://www.newpharmaitaly.it/boehringer-e-lilly-presentano-risultati-studio-carmelina/</link>
		
		<dc:creator><![CDATA[Elvis Kondi]]></dc:creator>
		<pubDate>Wed, 14 Nov 2018 15:57:48 +0000</pubDate>
				<category><![CDATA[Innovazione]]></category>
		<category><![CDATA[Bernard Zinman]]></category>
		<category><![CDATA[Boehringer Ingelheim]]></category>
		<category><![CDATA[CARMELINA®]]></category>
		<category><![CDATA[EASD]]></category>
		<category><![CDATA[Jeff Emmick]]></category>
		<category><![CDATA[Lilly]]></category>
		<category><![CDATA[linagliptin]]></category>
		<category><![CDATA[Waheed Jamal]]></category>
		<guid isPermaLink="false">http://www.newpharmaitaly.it/?p=3265</guid>

					<description><![CDATA[<p>I risultati di CARMELINA® sono stati presentati al 54° Congresso Annuale dell’Associazione Europea per lo Studio del Diabete (EASD) Boehringer Ingelheim ed Eli Lilly and Company (NYSE: LLY) hanno presentato i risultati completi dello studio sugli esiti cardiovascolari di lungo termine CARMELINA®, che ha valutato gli effetti della terapia con linagliptin sulla sicurezza cardiovascolare e [&#8230;]</p>
<p>L'articolo <a href="https://www.newpharmaitaly.it/boehringer-e-lilly-presentano-risultati-studio-carmelina/">Boehringer Ingelheim e Lilly presentano i risultati dello studio CARMELINA®</a> proviene da <a href="https://www.newpharmaitaly.it">Le Fonti New Pharma Italy</a>.</p>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
